1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Several Blockbuster Biopharmaceuticals Going Off-Patent
6.1.2 Next-Gen Business Models
6.1.3 Market Still In the Early Stage with High Growth Potential
6.1.4 Increasing Demand for Biosimilar Drugs Due To Their Cost-Effectiveness
6.2 Market Restraints
6.2.1 Concerns Regarding Substitutability and Interchangeability
6.2.2 Regulatory Uncertainty
6.2.3 Production Complexity
6.3 Opportunities
6.4 Challenges
7. Market Segmentation
7.1 By Product Class
7.1.1 Monoclonal Antibodies
7.1.1.1 Adalimumab
7.1.1.2 Infliximab
7.1.1.3 Rituximab
7.1.1.4 Trastuzumab
7.1.1.5 Bevacizumab
7.1.1.6 Others
7.1.2 Recombinant Hormones
7.1.2.1 Insulin
7.1.2.2 Human Growth Hormone
7.1.2.3 Follicle-Stimulating Hormone
7.1.2.4 Others
7.1.3 Recombinant Growth Factor
7.1.3.1 Granulocyte Colony-Stimulating Factor
7.1.3.2 Erythropoietin
7.1.3.3 Others
7.1.4 Immunomodulators
7.1.4.1 Interleukins
7.1.4.2 Cytokines
7.1.4.3 Immunomodulatory Imide Drugs (Imids)
7.1.4.4 Others
7.1.5 Anti-Inflammatory Agents
7.1.5.1 Tnf Inhibitors
7.1.5.2 Others
7.2 Segmentation by Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East and Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East and Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Pfizer Inc
9.2 Eli Lilly Aand Company
9.3 Celltrion Healthcare
9.4 Mylan NV
9.5 Novartis AG
9.6 Samsung Bioepis Co Ltd
9.7 Stada Arzneimittel AG
9.8 Teva Pharmaceutical Industries Ltd
9.9 Intas Pharmaceuticals Ltd
9.10 LG Life Sciences
9.11 Others
10. Future of The Market

Pfizer inc
Eli Lilly Aand Company
Celltrion Healthcare
Mylan nv
Novartis ag
Samsung Bioepis Co ltd
Stada Arzneimittel ag
Teva Pharmaceutical Industries ltd
Intas Pharmaceuticals ltd
LG Life Sciences